Pneumococcal antibody levels in children with PID receiving immunoglobulin

Pediatrics

Volumn 133, Issue 1, 2014, Pages

  Tuerlinckx, David ^a   Florkin, Benoit ^b   Ferster, Alina ^c   De Schutter, Iris ^d   Chantrain, Christophe ^e,f   Haerynck, Filomeen ^g   Philippet, Pierre ^f   Strengers, Paul ^h   Laub, Ruth ^h  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f Centre Hospitalier Chretien   (Belgium)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h Rode Kruis Vlaanderen   (Belgium)

Author keywords

Immunodeficiency; Intravenous immunoglobulin; Pediatric patients; Seroepidemiology; Specific antipneumococcal IgG

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PNEUMOCOCCAL ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CHILD HEALTH; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PNEUMOCOCCAL INFECTION; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; TREATMENT DURATION;

EID: 84891779778     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-1155     Document Type: Article

References (33)

1. Cox C, Link-Gelles R. Manual for the Surveillance of Vaccine-Preventable Disease. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2012
2. Black RE, Cousens S, Johnson HL, et al Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375 (9730): 1969-1987
3. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of antipneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25(19): 3816-3826
4. Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010;17(1): 134-142
5. Feavers I, Knezevic I, Powell M, Griffiths E; WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. Licensing of New Pneumococcal V. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July, 2008, Ottawa, Canada. Vaccine. 2009;27(28): 3681-3688
6. Sorensen RU, Leiva LE, Javier FC III, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. 1998;102(2): 215-221
7. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130 (suppl 3):S1-S24
8. Ballow M, Notarangelo L, Grimbacher B, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158(suppl 1): 14-22
9. Eijkhout HW, van Der Meer JW, Kallenberg CG, et al Inter-University Working Party for the Study of Immune Deficiencies. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135(3): 165-174
10. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010;137(1): 21-30
11. Mikolajczyk MG, Concepcion NF, Wang T, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol. 2004;11(6): 1158-1164
12. Lejtenyi D, Mazer B. Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J Allergy Clin Immunol. 2008;121(1): 254-255
13. Wasserman RL, Church JA, Peter HH, et al; IgPro10 in PID Study group. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci. 2009;37(3-4): 272-278
14. Chua I, Lagos M, Charalambous BM, Workman S, Chee R, Grimbacher B. Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG. J Allergy Clin Immunol. 2011;127(6): 1410-1411
15. Wasserman RL, Church JA, Stein M, et al. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. J Clin Immunol. 2012;32 (4): 663-669
16. Notarangelo L, Casanova JL, Conley ME, et al International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol. 2006;117(4): 883-896
17. Laub R, Baurin S, Timmerman D, Branckaert T, Strengers P. Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations. Vox Sang. 2010;99(3): 220-231
18. Gathmann B, Grimbacher B, Beauté J, et al ESID Registry Working Party. The European Internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol. 2009; 157(suppl 1): 3-11
19. Reed GF, Meade BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics. 1995;96(3 pt 2): 600-603
20. Schuerman L, Wysocki J, Tejedor JC, Knuf M, Kim KH, Poolman J. Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzymelinked immunosorbent assay with 22F adsorption. Clin Vaccine Immunol. 2011;18 (12): 2161-2167
21. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125: 1354-1360, e4
22. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1): 210-212
23. Bleasel K, Heddle R, Hissaria P, Stirling R, Stone C, Maher D. Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies. Intern Med J. 2012;42(3): 252-259
24. Guideline on Core SmPc for human normal immunoglobulin for intravenous administration (IVIg). EMA/CHMP/BPWP/94038/2007 rev. 3. London, UK: European Medicines Agency, Science Medicines Health
25. Esposito S, Droghetti R, Faelli N, et al. Serum concentrations of pneumococcal anticapsular antibodies in children with pneumonia associated with Streptococcus pneumonia infection. Clin Infect Dis. 2003; 37(9): 1261-1264
26. Yu J, Salamon D, Marcon M, Nahm MH. Pneumococcal serotypes causing pneumonia with pleural effusion in pediatric patients. J Clin Microbiol. 2011;49(2): 534-538
27. Pieretti M, Cunningham-Rundles C. Quantitation of antibodies in the sera of immunodeficient patients receiving monthly intravenous immune globulin (IVIg). J Allergy Clin Immunol. 2009;123(2):S14
28. Tuerlinckx D, Smet J, De Schutter I, et al. Evaluation of a WHO-validated serotypespecific serological assay for the diagnosis of pneumococcal etiology in children with community-acquired pneumonia. Pediatr Infect Dis J. 2013;32(7):e277-e284
29. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7 (10)
30. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378 (9807): 1962-1973
31. Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 2011;8(4):e1001017
32. Olarte L, Ampofo K, Stockmann C, et al. Invasive pneumococcal disease in infants younger than 90 days before and after introduction of PCV7. Pediatrics. 2013;132(1). Available at: www.pediatrics.org/cgi/content/full/132/1/e17
33. Liesenborghs L, Verhaegen J, Peetermans WE, Vandeven J, Flamaing J. Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002-2010. Vaccine. 2013;31(11): 1529-1534